Cantor Fitzgerald maintains Overweight on Summit Therapeutics

On Wednesday, Cantor Fitzgerald reiterated an Overweight rating on shares of Summit Therapeutics plc (NASDAQ:SMMT), following the company’s recent clinical trial updates. The company, now valued at over $20 billion, has seen its stock surge more than 630% over the past year, according to InvestingPro data. The firm’s analyst highlighted the potential of ivonescimab, a drug being developed by Summit Therapeutics, to become a new standard of care in non-small cell lung cancer (NSCLC).

The analyst from Cantor Fitzgerald emphasized the significance of the HARMONi-6 data, which supports the view of ivonescimab as a superior treatment compared to the current standard, pembrolizumab (pembro). The drug has now met its primary endpoint in three large, randomized NSCLC trials in China, suggesting a strong likelihood of ivonescimab establishing itself as a new standard across multiple patient subsets. InvestingPro analysis shows the company maintains a strong financial health score of GOOD, with liquid assets significantly exceeding short-term obligations.

Summit Therapeutics and its partner Akeso are conducting a robust clinical program for ivonescimab, including nine Phase 3 trials and multiple Phase 2 studies across various cancer types and treatment lines. The analyst pointed out the active nature of the drug and its multi-billion-dollar potential, even if it does not become the world’s largest ever drug.

The Cantor Fitzgerald analyst also addressed the binary outlook of ivonescimab, noting that the market either anticipates it to be a significant improvement over existing treatments with considerable market potential or sees it as undifferentiated and of limited value. The positive trial results contribute to de-risking the drug and enhancing its prospects.

Estimates from Cantor Fitzgerald suggest that sales in this class could reach $100 billion if ivonescimab proves to be the superior choice. These projections are based on the drug’s performance in clinical trials and its potential market impact.

Summit Therapeutics is focused on advancing the development of ivonescimab, with the latest data marking a positive step towards achieving their goal of redefining the standard of care for patients with NSCLC. With analyst price targets ranging from $30.82 to $46.32, and the stock showing a tendency to move independently from broader market trends (beta: -0.46), investors seeking deeper insights can access comprehensive analysis and 13 additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Summit Therapeutics has been the focus of several analyst reports, highlighting key developments for investors. JMP Securities maintained a Market Outperform rating with a $32 price target, driven by the potential of Summit’s drug, Ivo, and its upcoming Phase 3 HARMONi trial results, expected by mid-2025. Truist Securities also expressed confidence, maintaining a Buy rating and a $35 price target, emphasizing the anticipated outcomes of Summit’s pivotal HARMONi-2 and HARMONi-3 studies. Analysts at Truist, supported by a biostatistics expert, believe these studies could achieve statistical significance, potentially boosting the company’s stock performance.

Additionally, Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics, noting the early exercise of warrants by co-CEO and Chairman Bob Duggan as a positive indicator. Duggan’s acquisition of 4 million shares, executed well before the warrant expiration, is seen as a bullish move. Cantor Fitzgerald analysts also adjusted their financial model to account for increased costs due to royalties paid to Akeso, yet they maintained a valuation of $34.20 per share, suggesting significant upside potential. These recent developments underscore the ongoing interest and optimism surrounding Summit Therapeutics’ future prospects in the biotech industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.